Global Chimeric Antigen Receptor Cell Therapy Market Expected to Record Growth with Rapidly Growing Pharmaceutical Industry forecast to 2023

This research study added to the broad database of Market Research Hub (MRH) focusing on the “Chimeric Antigen Receptor Cell Therapy” delivers an in-depth outlook to present information about executive summary and key performance indicators. Furthermore, readers can gather knowledge about the economic status, demographics and competitive landscape which is prevailing in the concerned industry during the review period, 2018-2023. Overall, the purpose of this assessment is to present a clear picture highlighting the transformations expected to occur in the Chimeric Antigen Receptor Cell driven by major trends and opportunities. Chimeric Antigen Receptor Cell Therapy.

Request for free Sample @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2197346

Summary

Chimeric antigen receptor (CAR) cell therapy is an immuno-oncology (IO) approach that has gained increasing momentum in the past few years, with the approval of two new therapies in 2017 (US) and 2018 (EU). Novartis Kymriah (tisagenlecleucel) and Gilead Sciences Yescarta (axicabtagene ciloleucel) demonstrated impressive efficacy, and have both been approved for diffuse large B-cell lymphoma (DLBCL), with Novartis product approved for acute lymphocytic leukemia as well. Despite promising efficacy data, several challenges face the integration of CAR cell therapies into the clinic.
Complex manufacturing can lead to delayed patient access, as currently approved therapies can take up to three weeks to manufacture. High toxicity is also a key challenge for CAR cell therapies, as high rates of cytokine release syndrome and neurotoxicities (which can be fatal) require constant patient monitoring, potentially limiting CAR cell therapys use to centers of excellence. High production cost and hefty pricing are also challenges that CAR cell developers fail, as payers may hold negative perceptions of the nearly $0.5M pricepoint per dose.

This report provides an overview of the approved and late-stage pipeline CAR cell therapy landscape (including pre-clinical and Phase I CAR-NK cells), as well as a summary of key regulation processes in place in the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China). Key challenges faced by CAR cell therapies are summarized, as well as expected future development trends for the field.

Scope

Components of the slide deck include primary and secondary research -
- Quotes from eight US- and 5EU-based key opinion leaders, payers, and researchers
- Quotes from three Japan-based key opinion leaders
- Summary of CAR-cell therapy mechanism of action and history of development
- Overview of late-stage CAR cell pipeline and two marketed products
- Outline of regulatory pathways in place for CAR cell therapies across the 8MM, challenges that currently face CAR cell therapies, and future directions for CAR cell therapies
- Call-outs of key information and details
- Insight from Market Research Hubs specialist oncology analysts.

Reasons to buy

- Develop business strategies by understanding the challenges facing CAR cell therapies.
- Design development strategies by understanding innovative development strategies likely to improve CAR cell therapy perceptions and uptake in the future.

- Be acquainted with regulatory processes relevant to CAR cell therapies across the US, 5EU, Japan and China.
- Develop strategies by understanding expert perceptions of currently approved CAR cell therapies, challenges facing CAR cell therapies, and future directions of CAR cell therapy.

Table of Contents

1. Preface
1.1 Related Reports
1.2 Upcoming Reports
1.3 Abbreviations
2. Executive Summary
3. Introduction
3.1 Chimeric Antigen Receptor Cell Therapy Mechanism of
Action
3.2 History of Development of CAR Cell Products
3.3 Approved CAR-T Cell Products
3.4 Late-stage Pipeline CAR-T Cell Therapies
3.5 Preclinical Development of CAR Cell Products
4. Regulatory Pathways for CAR Cell Therapy
4.1 CAR Cell Therapy Regulation Overview in the 8MM
4.2 US CAR Cell Therapy Regulation
4.3 EU CAR Cell Therapy Regulation
4.4 Japan CAR Cell Therapy Regulation
4.5 China CAR Cell Therapy Regulation
5. Challenges for CAR Cell Therapy
5.1 Pricing Issues
5.2 Toxicity
5.3 Manufacturing
5.4 Resistance
6. Future Directions for CAR Cell Therapy
6.1 Allogeneic CAR Cell Therapies
6.2 Armored CARs
6.3 Dual Targeting CAR Cell Therapies
6.4 CAR Cell Therapy Combinations
6.5 CAR Natural Killer Cells
6.6 CAR Cell Therapies for Solid Tumors
7. Appendix
7.1 Primary Research
7.2 Sources
7.3 About the Authors
7.4 About Market Research Hub
7.5 Contact Us
7.6 Disclaimer

Continue...@@$

Enquire about this Report - https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2197346

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email : press@marketresearchhub.com
Website : www.marketresearchhub.com/

This release was published on openPR.